Advancement of modular therapies offers a new dynamic for today’s patients, but there’s still a need to maintain infection ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Overview of the Market  The global Cystic Fibrosis Market is valued at USD 10.3 Billion in 2024 and is projected to reach a ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

AAP FACTCHECK - A severely emaciated Palestinian child who appeared on the front page of newspapers around the world as a ...

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permane ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis ...

Tobacco smoke exposure may diminish the level of clinical benefit provided by ETI after 6 months in patients with cystic fibrosis.

Patient advocacy groups are urging the South African government to reopen an antitrust investigation into Vertex ...

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.